𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1

✍ Scribed by Dan C. Dimmitt; Youn Sung Choo; Lorene A. Martin; Thangam Arumugham; William F. Hahne; Scott J. Weir

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
766 KB
Volume
20
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.

✦ Synopsis

In this first part of a two-part investigation, the intravenous dose proportionality of dolasetron mesylate, a 5-HT 3 receptor antagonist, and the absolute bioavailability of oral dolasetron mesylate were investigated. In an open-label, randomized, four-way crossover design, 24 healthy men between the ages of 19 and 45 years received the following doses: 50, 100, or 200 mg dolasetron mesylate administered by 10-min intravenous infusion or 200 mg dolasetron mesylate solution administered orally. Serial blood and urine samples were collected for 48 h after dosing. Following intravenous administration, dolasetron was rapidly eliminated from plasma, with a mean elimination half-life (t 1/2 ) of less than 10 min. Dolasetron was rarely detected in plasma after oral administration of the 200 mg dose. Hydrodolasetron, the active primary metabolite of dolasetron, appeared rapidly in plasma following both oral and intravenous administration of dolasetron mesylate, with a mean time to maximum concentration (t max ) of less than 1 h. The mean t 1/2 of hydrodolasetron ranged from 6.6 -8.8 h. The plasma area under the concentration-time curve (AUC ( ) ) for both dolasetron and hydrodolasetron increased proportionally with dose over the intravenous dose range of 50 -200 mg dolasetron mesylate. Approximately 29 -33% and 22% of the dose was excreted in urine as hydrodolasetron following intravenous and oral administration of dolasetron, respectively. For dolasetron as well as hydrodolasetron, mean systemic clearance (Cl), volume of distribution (V d ), and t 1/2 were similar at each dolasetron dose. The mean 'apparent' bioavailability of dolasetron calculated using plasma concentrations of hydrodolasetron was 76%. The R( +) enantiomer of hydrodolasetron represented the majority of drug in plasma ( \ 75%) and urine ( \86%). Dolasetron was well tolerated following both oral and intravenous administration. Copyright

πŸ“œ SIMILAR VOLUMES

The pharmacokinetics of oral and intrave
The pharmacokinetics of oral and intravenous prenalterol in young, healthy volunteers
✍ A. F. Clarke; D. B. Jack; M. J. Kendall; S. R. Smith πŸ“‚ Article πŸ“… 1986 πŸ› John Wiley and Sons 🌐 English βš– 276 KB πŸ‘ 2 views

The pharmacokinetics of prenalterol in healthy young volunteers after i.v. and oral dosing has been studied. There is evidence of non-linearity following the i.v. dosing. Evidence of dose-dependent pharmacokinetics following i.v. dosing has been obtained. The sustained-release formulation is very ef

Single- and multiple-dose pharmacokineti
Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2
✍ Dan C. Dimmitt; Youn Sung Choo; Lorene A. Martin; Thangam Arumugham; William F. πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 132 KB πŸ‘ 2 views

The single-and multiple-dose pharmacokinetics and dose-proportionality of oral dolasetron and its active metabolites over the therapeutic dose range was investigated in 18 healthy men. In an open-label, randomized, complete three-way crossover design, each subject received three separate doses: 50,

Pharmacokinetics of intravenously and or
Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food
✍ David Tenero; David Martin; Bernard Ilson; John Jushchyshyn; Steve Boike; David πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 142 KB πŸ‘ 2 views

Eighteen healthy males received a single 300 mg oral dose of eprosartan as the commercial wet granulation formulation under fasting conditions and following a high-fat breakfast and a single 20 mg intravenous (i.v.) dose. The pharmacokinetics of i.v. eprosartan (mean 9 S.D.) were characterized by a

PHARMACOKINETICS AND SAFETY OF SINGLE IN
PHARMACOKINETICS AND SAFETY OF SINGLE INTRAVENOUS AND ORAL DOSES OF DOLASETRON MESYLATE IN HEALTHY WOMEN
✍ ANTHER C. F. KEUNG; HΓ‰LÈNE LANDRIAULT; MARC LEFEBVRE; DENIS GOSSARD; ELLEN E. DE πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 136 KB πŸ‘ 2 views

Twenty-four healthy women received 2Β΄4 mg kg 71 dolasetron mesylate (1Β΄8 mg kg 71 dolasetron base) by a 10 min intravenous administration and by oral administration. Pharmacokinetics of dolasetron and of its active reduced metabolite MDL 74 156 were monitored for 48 h in plasma. Urine was collected

Pharmacokinetics and bioavailability of
Pharmacokinetics and bioavailability of oral ergometrine in male volunteers
✍ A. N. J. A. De Groot; T. B. Vree; Y. A. Hekster; M. Van Den Biggelaar-Martea; P. πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 380 KB πŸ‘ 2 views

The aim of this investigation was to assess the pharmacokinetics and bioavailability of ergometrine in six human male subjects after an oral dose of 0.200 mg and after an intravenous dose of 0.075 mg of ergometrine maleate. A large variation in bioavailability of between 34% and 117% in the six volu